TYR — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Hexylresorcinol (SCHEMBL29107)	1.00	7/20
SCHEMBL69504	1.00	7/20
SCHEMBL69887	1.00	7/20
SCHEMBL70910	1.00	7/20
SCHEMBL69574	0.96	7/20
Taxiphyllin (SCHEMBL50174)	0.56	7/20
Mimosine (SCHEMBL41924)	1.00	6/20
L-Mimosine (SCHEMBL41925)	1.00	6/20
Rucinol (SCHEMBL68792)	1.00	6/20
SCHEMBL68200	0.77	6/20
SCHEMBL70564	0.72	6/20
SCHEMBL51397	0.71	6/20
SCHEMBL70013	0.66	6/20
SCHEMBL40375	0.65	6/20
SCHEMBL69697	0.58	6/20
Kojic Acid (SCHEMBL36895)	1.00	5/20
SCHEMBL43410	0.54	5/20
SCHEMBL43411	0.54	5/20
SCHEMBL43851	0.54	5/20
SCHEMBL43852	0.54	5/20

Clinical trials — most relevant to TYR by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Adjunctive Role of Vitamin C on Pigment Recurrence (Randomized Clinical and Histological Trial)	PHASE4	UNKNOWN
Ascorbic Acid Versus Diode Laser in the Treatment of Gingival Hyperpigmentation	PHASE4	COMPLETED
Topical Bimatoprost Solution 0.03%in Stable Vitiligo	PHASE4	WITHDRAWN
Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation	PHASE4	COMPLETED
Modified Jessner's Solution With Trichloroacetic Acid Versus Glycolic Acid With Trichloroacetic Acid	PHASE4	UNKNOWN
Evaluation of the Efficacy of Oral Tranexamic Acid and Glutathione-assisted Microneedling in Treatment of Melasma	PHASE2/PHASE3	NOT_YET_RECRUITING
Cysteamine Compared to Hydroquinone in Melasma	PHASE3	COMPLETED
Comparison of Effectiveness of Tranexamic Acid Mesotherapy Versus Glutathione Mesotherapy in Post Burn Facial Hyperpigmentation	PHASE2	ACTIVE_NOT_RECRUITING
Open-label, Single-arm, Proof of Concept Study in Subjects with Mild-to-moderate Facial Hyperpigmentation	PHASE2	WITHDRAWN
Efficacy of Microneedling With Vitamin C in Performing Gingival Depigmentation	PHASE1/PHASE2	NOT_YET_RECRUITING
Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase	PHASE2	COMPLETED
Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma	PHASE2	COMPLETED
Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery	PHASE2	COMPLETED
Novel Adjuvants for Peptide-Based Melanoma Vaccines	PHASE1	COMPLETED
Can Intravenous Vitamin C Improve Skin Hyperpigmentation in Long-Term Hemodialysis Patients?	nan	UNKNOWN
Vitamin C Depigmenattion Versus Conventional Technique	nan	COMPLETED
Efficacy and Tolerability of an Isobutylamido-thiazolyl-resorcinol Cream 0.2% for Facial Hyperpigmentation	nan	COMPLETED
Comparative Efficacy of Resveratrol 1 % Gel and Trichloroacetic Acid 20% in Treatment of Melasma: A Split-face Study	nan	NOT_YET_RECRUITING
The Role of Melanocyte in Basal Cell Carcinoma	nan	UNKNOWN
Fractional Erbium YAG Laser vs Intradermal and Systemic Tranexamic Acid	nan	RECRUITING
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo	nan	UNKNOWN
Biomarker for the Early Diagnosis and Monitoring in Tyrosinemia Type 1 (BioTyrosin)	nan	WITHDRAWN
Betamethasone Phonophoresis For Vitiligo	nan	RECRUITING
Microneedling With Vitamin C Versus Injectable Vitamin C for Depigmentation in Gingival Melanin Hyperpigmentation	nan	UNKNOWN
The Effect of Topical Almond Oil vs. Topical Retinol on The Appearance of Facial Wrinkles	nan	COMPLETED
Comparative Evaluation of Topical Metformin and Topical Tranexamic Acid in Melasma	nan	NOT_YET_RECRUITING
Efficacy and Tolerability of Test Product Versus Cysteamine 5% in Treatment of Facial Epidermal Melasma	nan	UNKNOWN
Clinical, Cellular, and Molecular Investigation Into Oculocutaneous Albinism	nan	COMPLETED
Harmonics-based in Vivo Optical Virtual Biopsy	nan	RECRUITING
The Effects of Lutein and Zeaxanthin Supplementation on Vision in Patients With Albinism	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a TYR binder may also engage these)

Protein	Name	Similarity
P55033	—	1.000	P55033 →
Q9BDE0	—	1.000	Q9BDE0 →
Q8MIU0	—	1.000	Q8MIU0 →
P11344	—	1.000	P11344 →
P54834	—	1.000	P54834 →
P55024	—	0.998	P55024 →
Q04604	—	0.995	Q04604 →
Q0MVP0	—	0.994	Q0MVP0 →
P55025	—	0.994	P55025 →
P55026	—	0.987	P55026 →
Q08410	—	0.980	Q08410 →
P40126	—	0.977	P40126 →
Q9VQH2	—	0.977	Q9VQH2 →
P07147	—	0.976	P07147 →
Q2VPW6	—	0.976	Q2VPW6 →
O93505	—	0.976	O93505 →
O35298	—	0.976	O35298 →
Q9WTZ2	—	0.976	Q9WTZ2 →
P55027	—	0.975	P55027 →
P29812	—	0.975	P29812 →
Q8R4K8	—	0.975	Q8R4K8 →
Q8HZK2	—	0.974	Q8HZK2 →
Q95119	—	0.974	Q95119 →
Q4R1H1	—	0.973	Q4R1H1 →
Q9ES45	—	0.973	Q9ES45 →
Q9Z2A8	—	0.973	Q9Z2A8 →
Q9WTZ3	—	0.973	Q9WTZ3 →
Q8WN57	—	0.973	Q8WN57 →
O18823	—	0.972	O18823 →
MBTPS1	Membrane-bound transcription factor site-1 protease	0.972	landscape →